



News

February 22, 2018

Cyberdyne has made an investment in CyberHeart to support their challenge to develop new medical software that enables non-invasive treatment of cardiac arrhythmias

~ Strengthening the development of innovative technology for early detection, diagnosis and treatment process of diseases in cardiovascular systems ~

TSUKUBA, Ibaraki, Japan and MOUNTAIN VIEW, California, USA – CYBERDYNE, INC. (“Cyberdyne”) and CyberHeart Inc. (“CyberHeart”) have announced that they have formed a capital tie-up (Cyberdyne has made an investment in CyberHeart). Concurrent with the capital tie-up, Cyberdyne and CyberHeart have also signed a memorandum of understanding for a further collaborative business relationship.

#### Background and Objective of the Alliance

While Cyberdyne advances its endeavor of Cybernic Treatment with Medical HAL for stroke patients, Cyberdyne also develops various technologies for prevention and diagnosis of stroke, cardiac infarction and disease related to cardiovascular system. One example of such technology that Cyberdyne is working on is the innovative Vital Sensor that enables daily monitoring of early symptoms such as hardening of arteries and cardiac function (cardiac arrhythmias) that may lead to aforementioned diseases. To treat cardiac arrhythmias that could be found faster by the Vital Sensor, Cyberdyne plans to develop non-invasive medical technology that is simpler compared to technologies that are currently used, in order to prevent stroke and cardiac infarction. CyberHeart is pioneering the development of medical software and methodologies for non-invasive treatment of cardiac arrhythmias. CyberHeart and Cyberdyne believe that their respective innovative technologies can be used in a collaborative manner to meet their strategic goals.

#### About CyberHeart

CyberHeart is a clinical development-stage company based at The Fogarty Institute for Innovation (“FII”) in Mountain View, California, that is developing stereotactic radiosurgery for cardiovascular conditions. While, stereotactic radiosurgery is widely used to treat tumors throughout the body because of its precision, the CyberHeart System <sup>(TM)</sup> includes proprietary technology and medical software that enables the use of the same hardware to non-invasively treat cardiac arrhythmias. CyberHeart was founded by Dr. Thomas Fogarty and Roderick Young. Dr. Fogarty is not only known

as a founder of the FII, but he is also an internationally recognized cardiovascular surgeon, inventor and entrepreneur. His inventions heavily influence the way surgery is performed today and include the “industry standard” Fogarty balloon catheter.

#### About Cyberdyne

Since its establishment as a venture company from the University of Tsukuba in 2004, CYBERDYNE, INC. has promoted the comprehensive development of various Cybernic Systems (Cybernic devices, Cybernic interfaces, etc.) that utilize Cybernic Technology from research and development to social implementation, aiming to tackle the various issues facing society. Cyberdyne has a developed business in the fields of medicine, welfare and daily living (including the work environment), and its main product, Robot Suit HAL®, is widely distributed not only in the medical and welfare fields but also in care support and labor support fields. In addition, new products such as Transport Robots and Cleaning Robots equipped with artificial intelligence and environment recognition functions, HAL Lumbar Type that reduces the load and stress on the lower back, smaller-sized HAL (Single-Joint Type), Vital Sensors for detecting arteriosclerosis and arrhythmia measurements are continuously being developed. For more details, please refer to the following website: [www.cyberdyne.jp/eng/](http://www.cyberdyne.jp/eng/).



Left: CYBERDYNE CEO Yoshiyuki Sankai, Right: Founder of CyberHeart Dr. Thomas Fogarty